KUALA LUMPUR, July 13 (Bernama) -- Recursion, a clinical stage TechBio company decoding biology to industrialise drug discovery, announced a US$50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). (US$1=RM4.61)
According to Recursion in a statement, the company plans to accelerate development of its artificial intelligence (AI) foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimise and distribute to biotechnology companies using NVIDIA cloud services.
“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery.
“With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space,” said Recursion Co-founder and Chief Executive Officer (CEO), Chris Gibson.
Meanwhile, NVIDIA founder and CEO, Jensen Huang said: “Generative AI is a revolutionary tool to discover new medicines and treatments.
“We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”
Recursion plans to utilise its vast proprietary biological and chemical dataset, to accelerate the training of foundation models on NVIDIA DGX Cloud for possible commercial licence/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.
NVIDIA will also help optimise and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise.
Recursion, through its recent acquisition of Valence Discovery, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratising access to large-scale models that have maximum impact in drug discovery.
-- BERNAMA
No comments:
Post a Comment